Loading
Led CheckMate 77T, one of the perioperative immunotherapy trials that changed how operable lung cancer is treated.
Tina Cascone was principal investigator of CheckMate 77T, which showed neoadjuvant nivolumab plus chemotherapy followed by adjuvant nivolumab improves event-free survival in resectable NSCLC, and led the NEOSTAR window trials that defined pathological response endpoints. Her laboratory studies the immune correlates of response to neoadjuvant therapy.
| Title | Journal | Year |
|---|---|---|
| Perioperative nivolumab in resectable lung cancer (CheckMate 77T) | NEJM | 2024 |
| Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial | Nature Medicine | 2021 |
| CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery | New England Journal of Medicine | 2022 |
Shares CheckMate 816, CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery, Resectable stage I to III non-small-cell lung cancer, Nivolumab and the tags lung, neoadjuvant.
Shares CheckMate 816, CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery, Resectable stage I to III non-small-cell lung cancer, Nivolumab.
Shares MD Anderson Cancer Center, Ipilimumab, Nivolumab, Immune checkpoint inhibitors and the tag neoadjuvant.
Shares Nivolumab, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tags lung, immunotherapy.
Shares KEYNOTE-671, CheckMate 816, Resectable stage I to III non-small-cell lung cancer, PD-1.
Shares PD-1, Immune checkpoint inhibitors and the tags neoadjuvant, immunotherapy.
Shares Ipilimumab, Nivolumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Resectable stage I to III non-small-cell lung cancer, PD-1, Non-small-cell lung cancer and the tags lung, immunotherapy.